What's in the Cards for Viatris Stock This Q4 Earnings?

Core Viewpoint - Viatris (VTRS) is set to report its fourth-quarter and full-year 2024 results on February 27, 2025, with revenue estimates at $3.60 billion and earnings at$0.57 per share [1]. Revenue Segments - Viatris reports financial results across five segments: Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China [2]. - Developed Markets are expected to contribute $2.2 billion in revenue, driven by new product performance and strong generics [3]. - Emerging Markets are projected to generate$539 million, supported by the expansion of the cardiovascular portfolio in Latin America [4]. - JANZ markets are estimated to bring in $366 million, fueled by new product launches in Australia and volume growth in Japan [4]. - Greater China is anticipated to yield$553 million, benefiting from strong demand across various channels [5]. Product Categories - The brand business constitutes the majority of Viatris' portfolio, with performance bolstered by the cardiovascular portfolio expansion and strong growth in Europe and Greater China [6]. - Generic growth is attributed to the strength in the European portfolio and complex products in North America [6]. Operating Expenses - Operating expenses are likely to have increased due to investments in SG&A for the eye care franchise, new product launches, and advancements in key R&D programs [7]. Share Price Performance - Viatris' shares have decreased by 13.2% over the past year, compared to a 15.8% decline in the industry [8]. Earnings Surprise History - The company has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average surprise of 0.33% [10]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Viatris, as it has an Earnings ESP of -3.51% and a Zacks Rank of 4 (Sell) [11][12].